Erectile dysfunction and cardiovascular disease

Mayo Clinic Proceedings

Volumn 79, Issue 6, 2004, Pages 782-794

  Russell, Shane T ^a   Khandheria, Bijoy K ^a   Nehra, Ajay ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; ERYTHROMYCIN; HEPARIN; NARCOTIC AGENT; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; VARDENAFIL;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DISEASE ASSOCIATION; DYSPEPSIA; ERECTILE DYSFUNCTION; GASTROINTESTINAL DISEASE; HEADACHE; HEART DISEASE; HEART INFARCTION; HUMAN; NOSE CONGESTION; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; RHINITIS; SEXUAL BEHAVIOR; SEXUAL FUNCTION; VISUAL DISORDER;

EID: 2542506334     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-6196(11)62632-3     Document Type: Review

References (90)

1. Muller JE. Sexual activity as a trigger for cardiovascular events: what is the risk? Am J Cardiol. 1999;84(5B):2N-5N.
2. NIH Consensus Development Panel on Impotence. NIH Consensus Conference: impotence. JAMA. 1993;270:83-90.
3. Zusman RM, Morales A, Glasser DB, Osterloh IH. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol. 1999;83(5A):35C-44C.
4. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54-61.
5. Feldman HA, Johannes CB, Derby CA, et al. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts Male Aging Study. Prev Med. 2000;30:328-338.
6. Kloner RA. Erectile dysfunction and cardiovascular risk factors. Hosp Pract (Off Ed). 2001;36:41-44, 49-51.
7. Virag R, Bouilly P, Frydman D. Is impotence an arterial disorder? a study of arterial risk factors in 440 impotent men. Lancet. 1985;1:181-184.
8. Muller JE, Mittleman A, Maclure M, Sherwood JB, Tofler GH, Determinants of Myocardial Infarction Onset Study Investigators. Triggering myocardial infarction by sexual activity: low absolute risk and prevention by regular physical exertion. JAMA. 1996;275:1405-1409.
9. Andersson K, Stief C. Penile erection and cardiac risk: pathophysiologic and pharmacologic mechanisms. Am J Cardiol. 2000;86(2A):23F-26F.
10. Kloner RA, Zusman RM. Cardiovascular effects of sildenafil citrate and recommendations for its use. Am J Cardiol. 1999;84(5B):11N-17N.
11. Nehra A. Intracavernosal therapy: when oral agents fail. Curr Urol Rep. 2001;2:468-472.
12. Rampin O, Giuliano F. Central control of the cardiovascular and erection systems: possible mechanisms and interactions. Am J Cardiol. 2000;86(2A):19F-22F.
13. Chung WS, Shim BS, Park YY. Hemodynamic insult by vascular risk factors and pharmacologic erection in men with erectile dysfunction: Doppler sonography study. World J Urol. 2000;18:427-430.
14. Dhabuwala CB, Kumar A, Pierce JM. Myocardial infarction and its influence on male sexual function. Arch Sex Behav. 1986;15:499-504.
15. Taylor HA Jr. Sexual activity and the cardiovascular patient: guidelines. Am J Cardiol. 1999;84(5B):6N-10N.
16. Greenstein A, Chen J, Miller H, Matzkin H, Villa Y, Braf Z. Does severity of ischemic coronary disease correlate with erectile function? Int J Impot Res. 1997;9:123-126.
17. Kawanishi Y, Lee KS, Kimura K, et al. Screening of ischemic heart disease with cavernous artery blood flow in erectile dysfunctional patients. Int J Impot Res. 2001;13:100-103.
18. Chiu AW, Chen KK, Chen MT, Chang LS, Chang MS. Penile brachial index in impotent patients with coronary artery disease. Eur Urol. 1991;19:213-216.
19. Newman HF, Marcus H. Erectile dysfunction in diabetes and hypertension. Urology. 1985;26:135-137.
20. McCulloch DK, Campbell IW, Wu FC, Prescott RJ, Clarke BF. The prevalence of diabetic impotence. Diabetologia. 1980;18:279-283.
21. Klein R, Klein BE, Lee KE, Moss SE, Cruickshanks KJ. Prevalence of self-reported erectile dysfunction in people with long-term IDDM. Diabetes Care. 1996;19:135-141.
22. Whitehead ED, Klyde BJ. Diabetes-related impotence in the elderly. Clin Geriatr Med. 1990;6:771-795.
23. Saenz de Tejada I, Goldstein I, Azadzoi K, Krane RJ, Cohen RA. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med. 1989;320:1025-1030.
24. Christ GJ, Stone B, Melman A. Age-dependent alterations in the efficacy of phenylephrine-induced contractions in vascular smooth muscle isolated from the corpus cavernosum of impotent men. Can J Physiol Pharmacol. 1991;69:909-913.
25. Wei M, Macera CA, Davis DR, Hornung CA, Nankin HR, Blair SN. Total cholesterol and high density lipoprotein cholesterol as important predictors of erectile dysfunction. Am J Epidemiol. 1994;140:930-937.
26. Mannino DM, Klevens RM, Flanders WD. Cigarette smoking: an independent risk factor for impotence? Am J Epidemiol. 1994;140:1003-1008.
27. Hirshkowitz M, Karacan I, Howell JW, Arcasoy MO, Williams RL. Nocturnal penile tumescence in cigarette smokers with erectile dysfunction. Urology. 1992;39:101-107.
28. Rosen MP, Greenfield AJ, Walker TG, et al. Cigarette smoking: an independent risk factor for atherosclerosis in the hypogastric-cavernous arterial bed of men with arteriogenic impotence. J Urol. 1991;145:759-763.
29. Xie Y, Garban H, Ng C, Rajfer J, Gonzalez-Cadavid NF. Effect of long-term passive smoking on erectile function and penile nitric oxide synthase in the rat. J Urol. 1997;157:1121-1126.
30. Jaffe A, Chen Y, Kisch ES, Fischel B, Alon M, Stern N. Erectile dysfunction in hypertensive subjects: assessment of potential determinants. Hypertension. 1996;28:859-862.
31. Hughes GS, Mathur RS, Margolius HS. Sex steroid hormones are altered in essential hypertension. J Hypertens. 1989;7:181-187.
32. Khaw KT, Barrett-Connor E. Blood pressure and endogenous testosterone in men: an inverse relationship. J Hypertens. 1988;6:329-332.
33. Hirshkowitz M, Karacan I, Gurakar A, Williams RL. Hypertension, erectile dysfunction, and occult sleep apnea. Sleep. 1989;12:223-232.
34. Shabsigh R, Fishman IJ, Schum C, Dunn JK. Cigarette smoking and other vascular risk factors in vasculogenic impotence. Urology. 1991;38:227-231.
35. Curb JD, Borhani NO, Blaszkowski TP, Zimbaldi N, Fotiu S, Williams W. Long-term surveillance for adverse effects of antihypertensive drugs. JAMA. 1985;253:3263-3268.
36. Wein AJ, Van Arsdalen KN. Drug-induced male sexual dysfunction. Urol Clin North Am. 1988;15:23-31.
37. Benet AE, Melman A. The epidemiology of erectile dysfunction. Urol Clin North Am. 1995;22:699-709.
38. Rosen RC, Kostis JB, Jekelis A, Taska LS. Sexual sequelae of antihypertensive drugs: treatment effects on self-report and physiological measures in middle-aged male hypertensives. Arch Sex Behav. 1994;23:135-152.
39. Rosen RC, Weiner DN. Cardiovascular disease and sleep-related erections. J Psychosom Res. 1997;42:517-530.
40. Horowitz JD, Goble AJ. Drugs and impaired male sexual function. Drugs. 1979;18:206-217.
41. Neri A, Aygen M, Zukerman Z, Bahary C. Subjective assessment of sexual dysfunction of patients on long-term administration of digoxin. Arch Sex Behav. 1980;9:343-347.
42. Weiss RJ. Effects of antihypertensive agents on sexual function. Am Fam Physician. 1991;44:2075-2082.
43. Warren SC, Warren SG. Propranolol and sexual impotence [letter]. Ann Intern Med. 1977;86:112.
44. Franzen D, Metha A, Seifert N, Braun M, Hopp HW. Effects of beta-blockers on sexual performance in men with coronary heart disease: a prospective, randomized and double blinded study. Int J Impot Res. 2001;13:348-351.
45. Srilatha B, Adaikan PG, Arulkumaran S, Ng SC. Sexual dysfunction related to antihypertensive agents: results from the animal model. Int J Impot Res. 1999;11:107-113.
46. Drugs that cause sexual dysfunction: an update. Med Lett Drugs Ther. 1992;34:73-78.
47. Mroczek WJ, Davidov M, Finnerty FA Jr. Prolonged treatment with clonidine: comparative antihypertensive effects alone and with a diuretic agent. Am J Cardiol. 1972;30:536-541.
48. Bansal S. Sexual dysfunction in hypertensive men: a critical review of the literature. Hypertension. 1988;12:1-10.
49. McCarron DA. Diuretic therapy for mild hypertension: the "real" cost of treatment. Am J Cardiol. 1984;53:9A-11A.
50. Meinhardt W, Kropman RF, Vermeij P, Nijeholt AA, Zwartendijk J. The influence of medication on erectile function. Int J Impot Res. 1997;9:17-26.
51. DeBusk R, Drory Y, Goldstein I, et al. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton Consensus Panel. Am J Cardiol. 2000;86(2A):62F-68F.
52. King BD, Pitchon R, Stern EH, Schweitzer P, Schneider RR, Weiner I. Impotence during therapy with verapamil. Arch Intern Med. 1983;143:1248-1249.
53. Bruckert E, Giral P, Heshmati HM, Turpin G. Men treated with hypolipidaemic drugs complain more frequently of erectile dysfunction. J Clin Pharm Ther. 1996;21:89-94.
54. Kostis JB, Rosen RC, Wilson AC. Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia. J Clin Pharmacol. 1994;34:989-996.
55. Altwein JE, Keuler FU. Oral treatment of erectile dysfunction with apomorphine SL. Urol Int. 2001;67:257-263.
56. Wallis RM, Corbin JD, Francis SH, Ellis P. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol. 1999;83(5A):3C-12C.
57. Kirby M, Jackson G, Betteridge J, Friedli K. Is erectile dysfunction a marker for cardiovascular disease? Int J Clin Pract. 2001;55:614-618.
58. Rendell MS, Rajfer J, Wicker PA, Smith MD, Sildenafil Diabetes Study Group. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. JAMA. 1999;281:421-426.
59. Kloner RA. Cardiovascular risk and sildenafil. Am J Cardiol. 2000;86(2A):57F-61F.
60. Webb DJ, Freestone S, Allen MJ, Muirhead GJ. Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol. 1999;83(5A):21C-28C.
61. Nehra A, Colreavy F, Khandheria BK, Chandrasekaran K. Sildenafil citrate, a selective phosphodiesterase type 5 inhibitor: urologic and cardiovascular implications. World J Urol. 2001;19:40-45.
62. Jackson G, Benjamin N, Jackson N, Allen MJ. Effects of sildenafil citrate on human hemodynamics. Am J Cardiol. 1999;83(5A):13C-20C.
63. Arruda-Olson AM, Mahoney DW, Nehra A, Leckel M, Pellikka PA. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial. JAMA. 2002;287:719-725.
64. Ishikura F, Beppu S, Hamada T, Khandheria BK, Seward JB, Nehra A. Effects of sildenafil citrate (Viagra) combined with nitrate on the heart. Circulation. 2000;102:2516-2521.
65. Stamler JS, Loh E, Roddy MA, Currie KE, Creager MA. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation. 1994;89:2035-2040.
66. Jackson G. Sexual intercourse and stable angina pectoris. Am J Cardiol. 2000;86(2A):35F-37F.
67. Vardenafil (levitra) for erectile dysfunction. Med Lett Drugs Ther. 2003;45:77-78.
68. Young JM. Vardenafil. Expert Opin Investig Drugs. 2002;11:1487-1496.
69. Goldstein I, Young JM, Fischer J, Bangerter K, Segerson T, Taylor T, Vardenafil Diabetes Study Group. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care. 2003;26:777-783.
70. Brock G, Nehra A, Lipschultz LI, et al. Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol. 2003;170(4, pt 1):1278-1283.
71. Hellstrom WJ, Gittelman M, Karlin G, et al, Vardenafil Study Group. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology. 2003;61(4, suppl 1):8-14.
72. Porst H, Young JM, Schmidt AC, Buvat J, International Vardenafil Study Group. Efficacy and tolerability of vardenafil for treatment of erectile dysfunction in patient subgroups. Urology. 2003;62:519-523.
73. Rajagopalan P, Mazzu A, Xia C, Dawkins R, Sundaresan P. Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol. 2003;43:260-267.
74. Gresser U, Gleiter CH. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil-review of the literature. Eur J Med Res. 2002;7:435-446.
75. Thadani U, Smith W, Nash S, et al. The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol. 2002;40:2006-2012.
76. Porst H. IC351 (tadalafil, Cialis): update on clinical experience. Int J Impot Res. 2002;14(suppl 1):S57-S64.
77. Holmes S. Tadalafil: a new treatment for erectile dysfunction. BJU Int. 2003;91:466-468.
78. Porst H, Padma-Nathan H, Giuliano F, Anglin G, Varanese L, Rosen R. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology. 2003;62:121-125.
79. Kimmel SE. Sex and myocardial infarction: an epidemiologic perspective. Am J Cardiol. 2000;86(2A):10F-13F.
80. Muller JE. Triggering of cardiac events by sexual activity: findings from a case-crossover analysis. Am J Cardiol. 2000;86(2A):14F-18F.
81. Drory Y, Fisman EZ, Shapira Y, Pines A. Ventricular arrhythmias during sexual activity in patients with coronary artery disease. Chest. 1996;109:922-924.
82. Hellerstein HK, Friedman EH. Sexual activity and the postcoronary patient. Arch Intern Med. 1970;125:987-999.
83. Tardif GS. Sexual activity after a myocardial infarction. Arch Phys Med Rehabil. 1989;70:763-766.
84. Stein RA. Cardiovascular response to sexual activity. Am J Cardiol. 2000;86(2A):27F-29F.
85. DeBusk RF. Evaluating the cardiovascular tolerance for sex. Am J Cardiol. 2000;86(2A):51F-56F.
86. Bohlen JG, Held JP, Sanderson MO, Patterson RP. Heart rate, rate-pressure product, and oxygen uptake during four sexual activities. Arch Intern Med. 1984;144:1745-1748.
87. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991;121(1, pt 2):293-298.
88. Jackson G. The use of sildenafil in heart disease [editorial]. Hosp Med. 2000;61:526-527.
89. Moss AJ, Benhorin J. Prognosis and management after a first myocardial infarction. N Engl J Med. 1990;322:743-753.
90. Nemec ED, Mansfield L, Kennedy JW. Heart rate and blood pressure responses during sexual activity in normal males. Am Heart J. 1976;92:274-277.